5-Butyl-3-cyclohexylmethyl-1-oxa-3,9-diaza-spiro[5.5]undecan-2-one | 862296-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 5-Butyl-3-cyclohexylmethyl-1-oxa-3,9-diaza-spiro[5.5]undecan-2-one
• 英文别名: 5-Butyl-3-(cyclohexylmethyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one
• CAS: 862296-85-3
• 化学式: C₁₉H₃₄N₂O₂
• 分子量: 322.491
• InChiKey: SMZPNDTYVMYTRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Butyl-3-cyclohexylmethyl-1-oxa-3,9-diaza-spiro[5.5]undecan-2-one 、 1-Cbz-4-哌啶酮 在 titanium(IV) isopropylate 、 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成
  参考文献：
  名称：

  Spiropiperidine CCR5 antagonists

  摘要：

  A novel series of CCR5 antagonists has been identified, utilizing leads from high-throughput screening which were further modified based on insights from competitor molecules. Lead optimization was pursued by balancing opposing trends of metabolic stability and potency. Selective and potent analogs with good pharmacokinetic properties were successfully developed. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.122
• 作为产物：
  描述：

  9-benzyl-5-butyl-3-cyclohexylmethyl-1-oxa-3,9-diaza-spiro[5.5]undecan-2-one 在 palladium dihydroxide 甲酸铵 、 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以79%的产率得到5-Butyl-3-cyclohexylmethyl-1-oxa-3,9-diaza-spiro[5.5]undecan-2-one
  参考文献：
  名称：

  Heterocyclic antiviral compounds

  摘要：

  本发明涉及式Ia和式Ib的哌啶衍生物，其取代基的定义如下，可用于治疗多种疾病，包括那些涉及CCR5受体调节的疾病。更具体地，本发明涉及1-氧杂-3,8-二氮杂-螺[4.5]癸烷-2-酮和1-氧杂-3,9-二氮杂-螺[5.5]十一烷-2-酮化合物及其相关衍生物，包括含有这些衍生物的组合物和这些衍生物的用途。本衍生物可用于治疗或预防HIV和遗传相关的逆转录病毒感染（以及由此引起的获得性免疫缺陷综合症，艾滋病），免疫系统疾病和炎症性疾病。

  公开号：

  US20050176703A1

文献信息

• Heterocyclic antiviral compounds
  申请人：Gabriel Deems Stephen

  公开号：US20050176703A1

  公开（公告）日：2005-08-11

  This invention relates to piperidine derivatives of formulae Ia and Ib with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases.

  本发明涉及式Ia和式Ib的哌啶衍生物，其取代基的定义如下，可用于治疗多种疾病，包括那些涉及CCR5受体调节的疾病。更具体地，本发明涉及1-氧杂-3,8-二氮杂-螺[4.5]癸烷-2-酮和1-氧杂-3,9-二氮杂-螺[5.5]十一烷-2-酮化合物及其相关衍生物，包括含有这些衍生物的组合物和这些衍生物的用途。本衍生物可用于治疗或预防HIV和遗传相关的逆转录病毒感染（以及由此引起的获得性免疫缺陷综合症，艾滋病），免疫系统疾病和炎症性疾病。
• CHEMOKINE CCR5 RECEPTOR MODULATORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1716156A2

  公开（公告）日：2006-11-02
• US7332500B2
  申请人：——

  公开号：US7332500B2

  公开（公告）日：2008-02-19
• US7538122B2
  申请人：——

  公开号：US7538122B2

  公开（公告）日：2009-05-26
• [EN] CHEMOKINE CCR5 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RECEPTEURS CCR5 DE CHIMIOKINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005075484A2

  公开（公告）日：2005-08-18

  This invention relates to piperidine derivatives of formulae (I) with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases.